drugset / Trial / NCT04432298
Study of the Efficacy and Safety of Intravenous Pamrevlumab, in Hospitalized Participants With Acute COVID-19 Disease
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study evaluates the efficacy and safety of intravenous (IV) infusions of pamrevlumab when compared with placebo in participants who are hospitalized with acute COVID-19 disease.
Timeline
- Start
- 2020-06-20
- Primary completion
- 2021-03-22
- Completion
- 2021-03-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pamrevlumab | Monoclonal antibody | 35 mg/kg | Intravenous |